Colin joined Alacrita from BioClinica, where he had provided medical imaging consulting services and served on a number of advisory boards, including bone safety for Rosiglitazone and Canagliflozin. His consulting activities have spanned small molecules, biologics and medical devices and he has supported several PMAs.
Colin has shared his expertise as a contributing author for more than 60 medical imaging publications in leading scientific journals. He is co-author of several books including Clinical Trials in Osteoporosis and Clinical Trials in Rheumatoid Arthritis and Osteoarthritis. His latest book, Medical Imaging in Clinical Trials, was published by Springer in February 2014.
For more than the past 25 years Colin has been working in pharmaceutical, device and biopharmaceutical services organizations. After his PhD he worked at Syntex Research, Europe and then moved to Procter & Gamble Pharmaceuticals. He moved from the UK to the USA in 1994 to create Bona Fide Ltd., a new start-up medical imaging service organization for a devices company: Lunar Corporation (now part of GE). Five years later Bona Fide was sold to BioClinica (previously Bio-Imaging Technologies). Colin served as an officer of the company for five years while it was publicly held on the NASDAQ, in roles including Senior Vice President of Medical Affairs and also Strategic Development.
Colin has a Bachelor’s degree from the University of Sheffield, UK and a PhD from the University of Hull, in the ultrasonic assessment of bone. He is a chartered scientist and a Fellow of the Institute of Physics and Engineering in Medicine and also a Fellow of the Institute of Clinical Research in the UK. He is an aviator and holds a pilot’s license.Back